N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L.
Miner SE, et al.
Am Heart J. 2004 Oct;148(4):690-5. doi: 10.1016/j.ahj.2004.05.015.
Am Heart J. 2004.
PMID: 15459602
Clinical Trial.